COGNITION THERAPEUTICS

Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease

05 Jul 2023 07:30:06 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

28 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023

27 Jun 2023 19:17:07 By Nasdaq GlobeNewswire

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

20 Jun 2023 07:30:15 By Nasdaq GlobeNewswire

Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences

02 Jun 2023 07:30:16 By Nasdaq GlobeNewswire

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

23 May 2023 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

18 May 2023 07:30:46 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

04 May 2023 16:05:54 By Nasdaq GlobeNewswire

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

01 May 2023 07:30:44 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

19 Apr 2023 07:30:52 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

12 Apr 2023 07:30:30 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

28 Mar 2023 07:30:40 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

27 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

23 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2023

21 Mar 2023 08:00:32 By Nasdaq GlobeNewswire

UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 Mar 2023 12:18:55 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

16 Mar 2023 07:30:53 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

15 Mar 2023 07:30:16 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference

07 Mar 2023 08:00:13 By Nasdaq GlobeNewswire

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

22 Feb 2023 08:00:02 By Nasdaq GlobeNewswire